Perspectives

1:02
Stephen Nimer: MDS highlights
Stephen Nimer
1:14
Horizon scan of MDS treatments
Alan List
0:43
MDS novel agents & HMAs
David Steensma
1:23
Patient advocates for clinical trials
Rena Buckstein
2:20
Emerging research in the MDS field
Argiris Symeonidis
2:10
Key themes from MDS 2020
Moshe Mittelman
0:54
HMAs are the standard, what are their limitations?
Alan List
2:15
Optimizing transplantation for MDS
Theo de Witte
3:04
Expanding MDS therapy options
Inga Mandac
1:21
Future treatment priorities for high-risk MDS
Yishai Ofran
1:12
Future MDS treatment options
Inga Mandac
2:18
Theo de Witte: an MDS transplant pioneer
Theo de Witte
1:59
MDS pathology and comorbidities
Theo de Witte
0:52
Inflammasome pathway: Target for new treatments?
Alan List
2:18
New targets for MDS treatment
Moshe Mittelman
2:20
CAR T-cell therapy access and reimbursement: the patient’s perspective
Bregje Verhoeven
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals